Cytogen Inc
217330
Company Profile
Business description
Cytogen Inc is a Korea based company engaged in developing HD Microporous chip using microfluidics and nanotechnology and it captures viable CTCS (circulating tumor cells) from cancer patients blood. The firm operates in two business areas including Liquid Biopsy Applications and Liquid Biopsy Platforms. Its services and products include: cancer drug development and monitoring, companion diagnostics, clinical research, CLIA-certified services, preclinical xenograft models, and liquid biopsy equipment.
Contact
128, Beobwon-ro
8th floor, Building A
Munjeong-dong, Munjeong SK V1
Songpa-gu
Seoul05854
KORT: +82 269251070
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
31 December 2026
Employees
45
Stocks News & Analysis
stocks
Will undervalued ASX share show progress in results?
Investors will get to see if the new strategy and capital management framework are working.
stocks
10 best US dividend aristocrats to buy now for 2026
These undervalued stocks with economic moats have increased their dividends for 25 consecutive years or more.
stocks
What to expect from the January Fed meeting
Central bankers are likely to hold interest rates steady, but Wall Street is focused on life after Powell.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,250.60 | 50.70 | -0.55% |
| CAC 40 | 8,081.16 | 71.66 | -0.88% |
| DAX 40 | 24,853.91 | 40.53 | -0.16% |
| Dow JONES (US) | 49,003.41 | 408.99 | -0.83% |
| FTSE 100 | 10,161.91 | 45.89 | -0.45% |
| HKSE | 27,826.91 | 699.96 | 2.58% |
| NASDAQ | 23,817.10 | 215.74 | 0.91% |
| Nikkei 225 | 53,358.71 | 25.17 | 0.05% |
| NZX 50 Index | 13,412.87 | 98.01 | -0.73% |
| S&P 500 | 6,978.60 | 28.37 | 0.41% |
| S&P/ASX 200 | 8,933.90 | 40.40 | -0.45% |
| SSE Composite Index | 4,151.24 | 11.33 | 0.27% |